Advertisement

Topics

Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent

2015-06-18 04:08:22 | BioPortfolio

Summary

The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.

Description

Intravitreal injections of anti-vascular endothelial growth factor agents are commonly used to treat a variety of retinal and choroidal neovascular diseases. The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure.

Although there is one study showed no significant changes in the intraocular pressure many retrospective studies showed the impacts on the intraocular pressure elevation. The investigators aim to prospective evaluate the intraocular pressure change in non-glaucomatous patients receiving an intravitreal anti-vascular endothelial growth factor therapy.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Intraocular Pressure

Intervention

Intravitreal injection (bevacizumab or ranibizumab)

Location

Weerawat Kiddee
Hatyai
Songkhla
Thailand
90110

Status

Completed

Source

Prince of Songkla University

Results (where available)

View Results

Links

Published on BioPortfolio: 2015-06-18T04:08:22-0400

Clinical Trials [2995 Associated Clinical Trials listed on BioPortfolio]

Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-rela...

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatme...

Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patient...

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evalua...

Efficacy of Retreatments With Intravitreal Bevacizumab

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab)...

PubMed Articles [5945 Associated PubMed Articles listed on BioPortfolio]

Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity.

To evaluate the short-term changes in intraocular pressure (IOP) after intravitreal injection of bevacizumab (IVB) in premature infants with retinopathy of prematurity (ROP).

The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab.

To compare the rates of infectious endophthalmitis following intravitreal injection of ranibizumab using prefilled syringes vs. conventional preparation.

COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.

To determine whether sterile preloading of anti-vascular endothelial growth factor agents reduces the risk of postintravitreal injection endophthalmitis.

Extended (≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials.

To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab ≥q12 or

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks.

Intravitreal anti-vascular endothelial growth factor (VEGF) injections are an effective treatment for neovascular age-related macular degeneration (nARMD). Bevacizumab appears to be a cost-effective o...

Medical and Biotech [MESH] Definitions

A form of GLAUCOMA in which chronic optic nerve damage and loss of vision normally attributable to buildup of intraocular pressure occurs despite prevailing conditions of normal intraocular pressure.

The pressure of the fluids in the eye.

Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.

Abnormally low intraocular pressure often related to chronic inflammation (uveitis).

A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.

More From BioPortfolio on "Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Searches Linking to this Trial